Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666.

Mariana M S OliveiraRoberta D'AulerioTracer YongMinghui HeMarisa A P BaptistaSusanne NylénLisa S Westerberg

Published in: British journal of cancer (2023)

Our data suggest that the small molecule inhibitor CK666 is a good candidate to enhance DC cross-presentation for cancer therapy.

Keyphrases